S&P 500   4,590.06 (+0.84%)
DOW   35,676.27 (+0.52%)
QQQ   383.15 (+0.83%)
AAPL   152.45 (+2.42%)
MSFT   322.85 (-0.10%)
FB   314.45 (+0.71%)
GOOGL   2,905.86 (-0.63%)
TSLA   1,069.50 (+3.05%)
AMZN   3,431.77 (+1.16%)
NVDA   246.62 (+0.86%)
BABA   169.75 (+0.31%)
NIO   39.82 (+1.30%)
CGC   13.06 (+2.19%)
GE   104.55 (+0.67%)
AMD   121.63 (-0.53%)
MU   69.69 (+2.12%)
T   25.50 (+1.76%)
F   17.00 (+9.61%)
ACB   6.98 (+2.05%)
DIS   170.20 (+0.38%)
PFE   43.29 (+0.74%)
BA   206.40 (-0.10%)
AMC   35.24 (+1.38%)
S&P 500   4,590.06 (+0.84%)
DOW   35,676.27 (+0.52%)
QQQ   383.15 (+0.83%)
AAPL   152.45 (+2.42%)
MSFT   322.85 (-0.10%)
FB   314.45 (+0.71%)
GOOGL   2,905.86 (-0.63%)
TSLA   1,069.50 (+3.05%)
AMZN   3,431.77 (+1.16%)
NVDA   246.62 (+0.86%)
BABA   169.75 (+0.31%)
NIO   39.82 (+1.30%)
CGC   13.06 (+2.19%)
GE   104.55 (+0.67%)
AMD   121.63 (-0.53%)
MU   69.69 (+2.12%)
T   25.50 (+1.76%)
F   17.00 (+9.61%)
ACB   6.98 (+2.05%)
DIS   170.20 (+0.38%)
PFE   43.29 (+0.74%)
BA   206.40 (-0.10%)
AMC   35.24 (+1.38%)
S&P 500   4,590.06 (+0.84%)
DOW   35,676.27 (+0.52%)
QQQ   383.15 (+0.83%)
AAPL   152.45 (+2.42%)
MSFT   322.85 (-0.10%)
FB   314.45 (+0.71%)
GOOGL   2,905.86 (-0.63%)
TSLA   1,069.50 (+3.05%)
AMZN   3,431.77 (+1.16%)
NVDA   246.62 (+0.86%)
BABA   169.75 (+0.31%)
NIO   39.82 (+1.30%)
CGC   13.06 (+2.19%)
GE   104.55 (+0.67%)
AMD   121.63 (-0.53%)
MU   69.69 (+2.12%)
T   25.50 (+1.76%)
F   17.00 (+9.61%)
ACB   6.98 (+2.05%)
DIS   170.20 (+0.38%)
PFE   43.29 (+0.74%)
BA   206.40 (-0.10%)
AMC   35.24 (+1.38%)
S&P 500   4,590.06 (+0.84%)
DOW   35,676.27 (+0.52%)
QQQ   383.15 (+0.83%)
AAPL   152.45 (+2.42%)
MSFT   322.85 (-0.10%)
FB   314.45 (+0.71%)
GOOGL   2,905.86 (-0.63%)
TSLA   1,069.50 (+3.05%)
AMZN   3,431.77 (+1.16%)
NVDA   246.62 (+0.86%)
BABA   169.75 (+0.31%)
NIO   39.82 (+1.30%)
CGC   13.06 (+2.19%)
GE   104.55 (+0.67%)
AMD   121.63 (-0.53%)
MU   69.69 (+2.12%)
T   25.50 (+1.76%)
F   17.00 (+9.61%)
ACB   6.98 (+2.05%)
DIS   170.20 (+0.38%)
PFE   43.29 (+0.74%)
BA   206.40 (-0.10%)
AMC   35.24 (+1.38%)
NASDAQ:NPCE

NeuroPace Stock Forecast, Price & News

$15.50
+0.12 (+0.78 %)
(As of 10/28/2021 10:51 AM ET)
Add
Compare
Today's Range
$15.50
$15.50
50-Day Range
$15.60
$23.78
52-Week Range
$15.02
$27.38
Volume
24 shs
Average Volume
93,662 shs
Market Capitalization
$376.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive NPCE News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.


About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NPCE
Employees
152
Year Founded
N/A

Sales & Book Value

Annual Sales
$41.14 million

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$376.59 million
Next Earnings Date
11/10/2021 (Confirmed)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

710th out of 1,372 stocks

Surgical & Medical Instruments Industry

74th out of 125 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












NeuroPace (NASDAQ:NPCE) Frequently Asked Questions

Is NeuroPace a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NeuroPace stock.
View analyst ratings for NeuroPace
or view top-rated stocks.

What stocks does MarketBeat like better than NeuroPace?

Wall Street analysts have given NeuroPace a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NeuroPace wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NeuroPace?

NeuroPace saw a increase in short interest in September. As of September 30th, there was short interest totaling 854,600 shares, an increase of 27.3% from the September 15th total of 671,400 shares. Based on an average daily volume of 52,900 shares, the days-to-cover ratio is currently 16.2 days. Approximately 12.7% of the company's shares are sold short.
View NeuroPace's Short Interest
.

When is NeuroPace's next earnings date?

NeuroPace is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for NeuroPace
.

How can I listen to NeuroPace's earnings call?

NeuroPace will be holding an earnings conference call on Wednesday, November 10th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) issued its earnings results on Thursday, August, 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.09. The company earned $12.63 million during the quarter, compared to analysts' expectations of $11.49 million.
View NeuroPace's earnings history
.

What guidance has NeuroPace issued on next quarter's earnings?

NeuroPace updated its FY 2021 earnings guidance on Thursday, September, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $47 million-$47 million, compared to the consensus revenue estimate of $46.95 million.

What price target have analysts set for NPCE?

5 analysts have issued 12-month target prices for NeuroPace's shares. Their forecasts range from $25.00 to $30.00. On average, they expect NeuroPace's share price to reach $26.80 in the next year. This suggests a possible upside of 72.9% from the stock's current price.
View analysts' price targets for NeuroPace
or view top-rated stocks among Wall Street analysts.

Who are NeuroPace's key executives?

NeuroPace's management team includes the following people:
  • Mr. Michael L. Favet, Pres, CEO & Director (Age 51)
  • Ms. Rebecca L. Kuhn, CFO, VP of Fin. & Admin. and Assistant Sec. (Age 60)
  • Ms. Irina Ridley, Gen. Counsel & Corp. Sec. (Age 35) (LinkedIn Profile)
  • Ms. Chi Nguyen, VP of Marketing (Age 44)
  • Mr. Mark S. Saxton, VP of Sales (Age 56)
  • Ms. Irene Thomas, VP of HR (Age 52)
  • Dr. Martha J. Morrell, Chief Medical Officer (Age 64)
  • Mr. Andre G. Marquette, Chief Commercial Officer

When did NeuroPace IPO?

(NPCE) raised $85 million in an IPO on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

What is NeuroPace's stock symbol?

NeuroPace trades on the NASDAQ under the ticker symbol "NPCE."

When did NeuroPace's lock-up period expire?

NeuroPace's lock-up period expired on Tuesday, October 19th. NeuroPace had issued 6,000,000 shares in its public offering on April 22nd. The total size of the offering was $102,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

How do I buy shares of NeuroPace?

Shares of NPCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroPace's stock price today?

One share of NPCE stock can currently be purchased for approximately $15.50.

How much money does NeuroPace make?

NeuroPace has a market capitalization of $376.59 million and generates $41.14 million in revenue each year.

How many employees does NeuroPace have?

NeuroPace employs 152 workers across the globe.

What is NeuroPace's official website?

The official website for NeuroPace is www.neuropace.com.

How can I contact NeuroPace?

The company can be reached via phone at 650-237-2700 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.